New research from Dana-Farber Cancer Institute shows that a new class of drug results in cell death in cancers, such as small ...

Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 MIAMI, FL / ACCESS Newswire / August 19, 2025 / MIRA Pharmaceuticals, Inc.

SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Dusquetide (SGX945) Granted Orphan Drug Designation for the Treatment ...

The trial aims to assess the regimen over a 90-day period for those with a presumptive diagnosis of the condition.

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

Omer Trivizki discusses promising results of VOY-101, a gene therapy for geographic atrophy, highlighting safety and next ...

NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global ...

The FDA has approved Insmed’s Brinsupri™ (brensocatib 10 mg and 25 mg tablets) as the first drug authorized to treat ...

In the longevity and wellness space, Niagen Bioscience is charting a course defined by both scientific rigor and an ...

Data show that the cancer vaccine Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival in ...

A new cancer vaccine targeting KRAS gene mutations shows promise in preventing pancreatic and colorectal cancer recurrence in ...